Critical Review: Genetic Technologies (NASDAQ:GENE) & Revolution Medicines (NASDAQ:RVMD)

Genetic Technologies (NASDAQ:GENEGet Free Report) and Revolution Medicines (NASDAQ:RVMDGet Free Report) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, dividends, profitability, risk and valuation.


This table compares Genetic Technologies and Revolution Medicines’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Genetic Technologies N/A N/A N/A
Revolution Medicines N/A -36.41% -32.13%

Analyst Recommendations

This is a summary of recent ratings and price targets for Genetic Technologies and Revolution Medicines, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Genetic Technologies 0 0 0 0 N/A
Revolution Medicines 0 0 9 1 3.10

Revolution Medicines has a consensus target price of $43.20, indicating a potential upside of 12.71%. Given Revolution Medicines’ higher possible upside, analysts clearly believe Revolution Medicines is more favorable than Genetic Technologies.

Institutional & Insider Ownership

0.6% of Genetic Technologies shares are held by institutional investors. Comparatively, 94.3% of Revolution Medicines shares are held by institutional investors. 6.5% of Genetic Technologies shares are held by insiders. Comparatively, 8.0% of Revolution Medicines shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares Genetic Technologies and Revolution Medicines’ revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Genetic Technologies $5.85 million 1.49 -$7.91 million N/A N/A
Revolution Medicines $11.58 million 546.12 -$436.37 million ($3.75) -10.22

Genetic Technologies has higher earnings, but lower revenue than Revolution Medicines.

Risk and Volatility

Genetic Technologies has a beta of 1.21, suggesting that its stock price is 21% more volatile than the S&P 500. Comparatively, Revolution Medicines has a beta of 1.46, suggesting that its stock price is 46% more volatile than the S&P 500.


Revolution Medicines beats Genetic Technologies on 8 of the 11 factors compared between the two stocks.

About Genetic Technologies

(Get Free Report)

Genetic Technologies Limited, a molecular diagnostics company, provides predictive genetic testing and risk assessment tools to help physicians manage people's health in the America, Canada, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. It operates through AffinityDNA, EasyDNA, and GeneType/Corporate segments. The company offers BREVAGenplus, a clinically validated risk assessment test for non-hereditary breast cancer. It also markets BREVAGenplus to healthcare professionals in breast health care and imaging centers, as well as to obstetricians/gynecologists and breast cancer risk assessment specialists, such as breast surgeons. In addition, the company offers various cancer risk assessment tests under the GeneType for Colorectal Cancer and GeneType for Breast Cancer brand names; and develops other risk assessment tests across a range of diseases, which include colorectal cancer, ovarian cancer, prostate cancer, coronary artery, type 2 diabetes, pancreatic cancer, melanoma, and atrial fibrillation. Further, it offers genetic testing services, including medical, animal, forensic, and plant testing. The company has research and collaboration agreements with the University of Melbourne for the development and commercialization of a novel colorectal cancer risk assessment test; and Memorial Sloan Kettering Cancer Center of New York and University of Cambridge, that assess the conflict among BRCA mutation carriers considering preventive surgery. Genetic Technologies Limited was incorporated in 1987 and is headquartered in Fitzroy, Australia.

About Revolution Medicines

(Get Free Report)

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

Receive News & Ratings for Genetic Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genetic Technologies and related companies with's FREE daily email newsletter.